CMS “Systems Approach” To Permit Equitable QC Testing Options Under CLIA
This article was originally published in The Gray Sheet
Executive Summary
CLIA-regulated diagnostic manufacturers can change their package inserts and work with labs to take advantage of increased flexibility granted under CMS' new equitable quality control (EQC) testing options
You may also be interested in...
CMS 2005 Stakeholder Meeting To Discuss Future Of CLIA Quality Control
CMS intends to address diagnostic quality control issues, such as whether FDA will enforce CLIA-related regulations on package inserts, during a March 18, 2005 stakeholder meeting
CMS 2005 Stakeholder Meeting To Discuss Future Of CLIA Quality Control
CMS intends to address diagnostic quality control issues, such as whether FDA will enforce CLIA-related regulations on package inserts, during a March 18, 2005 stakeholder meeting
Bio-Rad Defends Labeling Under First Amendment, Prior FDA Inaction
Disclaimers on unified labeling for lab "control products" that list unapproved tests are legal and do not promote off-label use, Bio-Rad maintains in a citizen petition recently filed with FDA